Pro Medicus Limited (ASX: PME)- Pro Medicus’ shares are on fire today

pro medicus

Pro Medicus’ (ASX: PME) stock jumped 6.869% to $10.890 on 3 September 2018 after the healthcare technology company recently announced strong full years results for the period ended 30 June 2018.

Profit after tax has gone up by 36.7% to $12.74 million on the back of significant increase in the performance of the North American and European operations in addition to the unrealized foreign currency gains.

Underlying profit, which excludes currency movements was $12.57 million an increase of 27.4% from the previous year. Full year revenue of the group increased from $31.62 million in FY17 to $36.02 million in FY18, an increase of 13.9%. Revenue from European operation increased by 33.2% while North America’s revenue has gone up by 18.4% on FY17. [optin-monster-shortcode id=”wxhmli4jjedneglg1trq”]

During FY18 company has completed $18 million Yale New Haven contract, I-Med renewal and extension contract and $15 million Visage Open Archive deal with Mercy health.

Board has declared final dividend of 3.5 cents per share in addition to interim dividend of 2.5 cents paid during FY18. The fully franked final dividend is payable on 27 September 2018 with the record date of 7 September 2018.

The company seem to be positioned to take advantage of the emerging Artificial Intelligence technology in its healthcare imaging products.

Dividend Stocks To Buy

The Income available from dividends remains attractive for many investors.

We take a look at the best yields on the market and assess what they say about a company’s prospect.

One Thing is certain, though, Australia interest rates are still low, making income difficult to come by and keeping the focus for many investors on high yielding stocks. Kalkine’s team of analysts bought you handpicked report for “Top 25 Dividend Stocks For 2018.”

ASX-relevant Special Reports are published year-round to provide a detailed analysis into an investing opportunity or a potential risk to your portfolio.

Click here to get your free report.


The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. and associated websites are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). website), employees and/or associates of Kalkine Pty Ltd do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.

Checkout our Free Dividend Stocks Report

Specially made for income-hungry investors, Invest in growing Franked Dividends an opportunity that should not be missed.

6 Cannabis Stocks under Investor’s Limelight…

Cannabis companies that sell both medicinal weed and recreational pot. Marijuana stocks to look at. Marijuana mergers and acquisitions. Dispensary data analytics. Upcoming marijuana IPO’s Those phrases have become increasingly common as marijuana legalization spreads.

Global spending on legal cannabis is expected to grow 230% to $32 billion in 2020 as compared to $9.5 in 2017, according to Arcview Market Research and BDS Analytics. As of June 29, 2018 the United States Marijuana Index, despite a lot of uncertainty around regulations, has over the past 1 year gained 71.49%, as compared to about 12% gain seen by the S&P 500.

Click here for your FREE Report